Behçet disease - Pipeline Insight, 2024

This Behçet disease - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Behçet disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Behçet disease Understanding

Behçet disease: Overview

Behcet disease was first described in 1937 by Hulusi Behçet from Istanbul, who described three patients with oral and genital ulcerations, uveitis, and erythema nodosum. Other clinical features were identified later and were added to the disease spectrum. Behcet disease is an auto-inflammatory systemic vasculitis of unknown etiology. It is characterized by mucocutaneous manifestations, including recurrent oral and genital ulcerations, ocular manifestations, especially chronic relapsing uveitis and systemic vasculitis involving arteries and veins of all sizes. It is also known as Behcet syndrome and malignant aphthosis.

Behçet disease - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Behçet disease pipeline landscape is provided which includes the disease overview and Behçet disease treatment guidelines. The assessment part of the report embraces, in depth Behçet disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Behçet disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Behçet disease R&D. The therapies under development are focused on novel approaches to treat/improve Behçet disease.

This segment of the Behçet disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Behçet disease Drugs
Canakinumab: Novartis Canakinumab is a human monoclonal antibody designed to target interleukin-1ß with high affinity and selectivity, in turn preventing it from activating its downstream receptors. This mode of action makes canakinumab an effective anti-inflammatorymolecule.

Behçet disease: Therapeutic Assessment

This segment of the report provides insights about the Behçet disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Behçet disease

There are approx. 4+ key companies which are developing the therapies for Behçet disease. The companies which have their Behçet disease drug candidates in the most advanced stage, i.e. Phase II include Novartis.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Behçet disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Behçet disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Behçet disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Behçet disease drugs.

Behçet disease Report Insights

• Behçet disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Behçet disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Behçet disease drugs?
• How many Behçet disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Behçet disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Behçet disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Behçet disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Tianjin Hemay Biotech
• Novartis
• AstraZeneca
• Kangpu Biopharmaceuticals

Key Products

• Mufemilast
• Canakinumab
• RIST 4721
• KPG612